Affinity Asset Advisors LLC Acquires Shares of 2,825,000 ProQR Therapeutics (NASDAQ:PRQR)

Affinity Asset Advisors LLC bought a new position in ProQR Therapeutics (NASDAQ:PRQR) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 2,825,000 shares of the biopharmaceutical company’s stock, valued at approximately $7,486,000. ProQR Therapeutics makes up 1.0% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 28th largest position.

Several other hedge funds have also made changes to their positions in PRQR. Jump Financial LLC acquired a new stake in ProQR Therapeutics during the 4th quarter valued at $71,000. Walleye Capital LLC purchased a new position in shares of ProQR Therapeutics during the fourth quarter valued at $1,196,000. XTX Topco Ltd acquired a new position in ProQR Therapeutics during the fourth quarter valued at $163,000. Raymond James Financial Inc. purchased a new stake in ProQR Therapeutics in the 4th quarter worth about $260,000. Finally, Invesco Ltd. purchased a new stake in ProQR Therapeutics in the 4th quarter worth about $32,000. Hedge funds and other institutional investors own 32.65% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on PRQR shares. Chardan Capital reiterated a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a report on Friday, March 14th. HC Wainwright upped their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, March 14th. Oppenheimer started coverage on shares of ProQR Therapeutics in a research note on Friday, January 10th. They set an “outperform” rating and a $15.00 target price for the company. Finally, Citigroup upgraded ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

ProQR Therapeutics Stock Performance

Shares of PRQR opened at $1.18 on Tuesday. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $4.62. The firm has a market capitalization of $124.15 million, a P/E ratio of -3.69 and a beta of 0.25. The company has a 50-day simple moving average of $1.82 and a 200-day simple moving average of $2.54.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).